Camidanlumab Tesirine
ADC Therapeutics
['hodgkin', 'pivotal', 'lymphoma']
we're pleased to announce results from the pivotal phase 2 clinical trial of our cd25-targeted #antibodydrugconjugate for patients with relapsed or refractory hodgkin #lymphoma, which were presented today at #eha2022. read more: 
Leading the development & commercialization of next-generation antibody drug conjugates with highly potent and targeted pyrrolobenzodiazepine dimer technology